Document |
Document Title |
WO/2023/097308A1 |
Embodiments of the present application relate to the preparation of 2'-O-protected nucleoside phosphoramidites and conjugation of the 2'-O-protected nucleoside to a solid support. More specifically, the present application relates to nuc...
|
WO/2023/093722A1 |
The present application relates to a compound having a structure shown in formula (I), wherein n1 is an integer selected from 4-21, and n2 is an integer selected from 1-2. The present invention also relates to a composition, comprising a...
|
WO/2023/023513A9 |
Provided herein are stable, modified oligonucleotides comprising a 5'-alkyl phosphate or derivatives thereof and methods for preparing the same.
|
WO/2023/097291A1 |
Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to ...
|
WO/2023/089617A1 |
The present invention relates to conjugates comprising amino-acid-cytarabine, in particular, conjugates of cytarabine and two or more amino acids selected from alanine, aspartic acid, glutamic acid, asparagine, or glutamine for use in th...
|
WO/2023/086557A1 |
Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives o...
|
WO/2023/083295A1 |
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions comprising thereof, to the preparation method thereof, and to the use and method of the ester derivatives of N 4-hydroxycyti...
|
WO/2023/085242A1 |
The present invention provides an antiviral agent that comprises a compound represented by general formula (A-1) or (A-2) [wherein: R1 represent O, S, Se or =N-RO11; R2 represents O, S, Se or =N-OR11; R3 represents -O-R12, -S-R13 or a gu...
|
WO/2023/077503A1 |
A method for increasing the bulk density of a crystal of nicotinamide mononucleotide (NMN), and a crystal of NMN. The method comprises: dissolving NMN in water to obtain an aqueous solution of NMN; subjecting the aqueous solution of NMN ...
|
WO/2023/081105A1 |
Provided herein are cyclic phosphoramidate compounds, their preparation and their uses, such as treating liver or non-liver diseases or conditions.
|
WO/2023/080253A1 |
The present invention provides a method for producing mixed crystals of 5'-disodium guanylate (G) and 5'-disodium inosinate (I), the method including a first crystallization step for forming mixed crystals including G and I in an I/G rat...
|
WO/2023/076687A1 |
Provided herein are compositions, devices, systems and methods for DNA oligomer synthesis. Further provided are devices comprising addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.). ...
|
WO/2023/076392A1 |
The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, c...
|
WO/2023/074843A1 |
[Problem] The problem of the present invention is to provide: a novel oligosaccharide that can be used in order to manufacture a 2-branched glycan having an α2,6-sialic acid structure at a non-reducing end; a method for manufacturing th...
|
WO/2023/071293A1 |
Disclosed in the present application is a method for preparing molnupiravir, which belongs to the technical field of drug preparation. The preparation method comprises the following steps: (1) adding the compound of formula (I) to an alc...
|
WO/2023/070010A1 |
The aspects of this disclosure relate to luminescently labeled nucleic acid nanostructure as well as methods and compositions for the detection and/or sequencing of one or more target molecules derived from a sample. The invention may ut...
|
WO/2023/069495A1 |
The present disclosure relates generally to 2'-geminal substituted nucleosides and nucleotides, and oligonucleotides and dsRNA molecules comprising such 2'-geminal substituted nucleosides and nucleotides.
|
WO/2023/069599A1 |
Embodiments of the present application relate to porous polymeric beads solid support for use in oligonucleotide synthesis and the method of producing and using the same. Further embodiments relate to porous polymeric beads and method fo...
|
WO/2023/065683A1 |
Disclosed are a novel deuterated purine nucleoside compound as shown in formula I, or a pharmaceutically acceptable salt, an isomer, or a prodrug thereof. Also disclosed are a preparation method for said deuterated compound, a compositio...
|
WO/2023/063168A1 |
The present invention addresses the problem of providing a composition useful for controlling pests. Disclosed is a pest controlling composition comprising a compound represented by formula (1) (in the formula: R1 and R2 independently re...
|
WO/2023/061319A1 |
Disclosed is a series of tricyclic heterocyclic derivatives. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
WO/2023/054708A1 |
[Problem] To provide a novel method for producing a 2'-carbamoylalkyl-modified nucleoside having a pyrimidine base. [Solution] Provided are: a method for producing a 2'-carbamoylalkyl-modified uridine compound, characterized in that an a...
|
WO/2023/053039A1 |
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...
|
WO/2023/051675A1 |
The invention concerns compounds of Formula (X) which modulate, especially agonize alpha kinase 1 (ALPK1) and are useful for treating a condition, disease or disorder in which a decrease or increase in ALPK1 activity contributes to the p...
|
WO/2023/052468A1 |
The present application relates to novel nucleoside analogues of formula (I) and compositions containing said nucleoside analogues. Moreover, the present application provides processes for the preparation of the disclosed compounds, as w...
|
WO/2023/052970A1 |
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer, or salt thereof, wherein R1, R2, R3, R4, R5, L1a, L1b, L2, L3, L4, L5, L6, L7, M1, M2, q, w, m ...
|
WO/2023/047141A1 |
Provided herein are analogues of S-adenosyl-L-methionine, methods of their preparation, and complexes and kits comprising the analogues. Said analogues find use in modifying, labelling and analysing a target molecule such as a nucleic acid.
|
WO/2023/049258A1 |
The present disclosure provides to linker compounds of Formula (I) or (II): pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, compounds of formula (l-A) are disclosed. The present disclos...
|
WO/2023/041786A1 |
The invention provides novel 5 -Fluorouracil derivatives that are useful as prodrugs for cancer treatment. 5 -Fluorouracil nucleoside triphosphates are masked at the terminal phosphate of the triphosphate group with residues that are cle...
|
WO/2023/039005A2 |
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
|
WO/2023/034617A1 |
The present invention is directed to new methods for the treatment of an infection by a virus from the genus Flavivirus, particularly Dengue fever virus, Yellow Fever virus, Zika virus, and West Nile virus, in a host in need thereof, typ...
|
WO/2023/031481A1 |
The present invention relates to a method for preparing cyclic guanosine-3', 5'- monophosphate analogues. The invention also relates to the new cyclic guanosine-monophosphate analogues and intermediates obtained by the method.
|
WO/2023/033481A1 |
The present invention relates to an adenosine diphosphate-ribose (ADP-ribose) binding peptide having anticancer activity and, more particularly, to an ADP-ribose binding peptide of a specific amino acid sequence, a modified product there...
|
WO/2023/027178A1 |
The present invention relates to a method for producing a cytidine-5'-diphosphate compound, the method comprising: (1) a step in which a solution containing a cytidine-5'-diphosphate compound is brought into contact with a basic ion exch...
|
WO/2023/026449A1 |
The purpose of the present invention is to provide a method for producing a cytidine 5'-diphosphate compound, in which cytidine 5'-phosphate can be efficiently separated from a crude cytidine 5'-diphosphate compound to concentrate the cy...
|
WO/2023/027065A1 |
The present invention provides a novel method for producing a 2'-modified guanosine compound represented by the formula. In the formula, R1 and R2 may be the same or different, and each represents a hydrogen atom, an optionally substitut...
|
WO/2023/023550A1 |
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linkage. In some embod...
|
WO/2023/021286A2 |
The present invention relates to novel nucleotide complexes which enhance the enzymatic production of DNA. The nucleotide complexes includes a divalent cation at a ratio of 0.2-1.5 divalent cations per nucleotide, whilst monovalent ions ...
|
WO/2023/019670A1 |
A purification method for fluorescein-labeled nucleoside triphosphate, specifically comprising: purifying a fluorescein-labeled nucleoside triphosphate crude product by means of liquid chromatography, and collecting a target fraction, wh...
|
WO/2023/016999A2 |
GalNAc monomers and GalNAc-oligonucleotide conjugates made using said GalNAc monomers, for example, GalNAc-bearing nucleic acids, e.g. sa-RNAs and siRNAs that may be useful in regulating expression of a target gene.
|
WO/2023/017152A1 |
The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X1, X2, X3, X4, R1, R2, R3, R5...
|
WO/2023/001982A1 |
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adduc...
|
WO/2023/004130A1 |
Methods for synthesizing Bisphosphocins use chemical modification of dialcoholic compounds avoiding the use of tetrazole and tertiary butyl hydroperoxide.
|
WO/2023/004438A2 |
The present application provides compounds and methods for identifying a modulator of a protein of interest using TR-FRET donor attached to the protein of interest and a tracer containing TR-FRET acceptor.
|
WO/2023/000708A1 |
Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory eff...
|
WO/2023/288045A2 |
The present disclosure relates monomers and methods for synthesisizing oligonucleotides comprising 2,6-diaminopurine (DAP) and 2-aminoadenine conjugates.
|
WO/2023/288047A2 |
The present disclosure relates generally to monomers and methods for conjugating one or more ligands to oligonucleotides by Click chemistry at the anomeric site of pentose sugars, such as pentose sugars or hexose sugars.
|
WO/2023/282306A1 |
The present invention provides a pharmaceutical composition for treating or preventing a disease associated with the reduction or defect of the modification of 5-taurinomethyluridine (τm5U) in mitochondrial tRNA, the pharmaceutical comp...
|
WO/2023/282704A1 |
The present invention relates to an RNAi agent targeting a mitochondrial amidoxime reducing component 1 (MARC1) gene, and a use thereof, and, more specifically, to: an RNAi agent comprising an antisense strand having sequence complementa...
|
WO/2023/280156A1 |
Provided is a modified nucleoside or nucleotide. The modified nucleoside or nucleotide contains an N or S atom at a 3' position of a sugar ring, and can be used for NGS sequencing. Further provided are a kit comprising the modified nucle...
|